

Please replace the paragraph beginning at page 60, line 2, with the following rewritten paragraph:

**Example 25**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA<sub>n</sub>-MPA)-NH<sub>2</sub>·2TFA (SEQ ID NO: 66)**

Please replace the paragraph beginning at page 61, line 3, with the following rewritten paragraph:

A peptide stability assay was performed. (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub>·2TFA (SEQ ID NO: 67) was synthesized as described above and was identified MPA-K5. The non-modified counterpart peptide Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub> (SEQ ID NO: 12) was also synthesized as described above without the addition of 3-MPA and identified as K5.

### REMARKS

Reconsideration is respectfully requested. This is in response to the Notice of Non-Compliant Amendment (37 CFR 1.121) dated March 25, 2002, for which a response is due on April 25, 2002. This response includes a clean version of the replacement paragraphs in the specification, and therefore, the amendment filed on February 26, 2002 is now compliant with rule 1.121.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 500862002200.

Respectfully submitted,

Dated: April 9, 2002

By: Michael R. Ward  
Michael R. Ward  
Registration No. 38,651

Morrison & Foerster LLP  
425 Market Street  
San Francisco, California 94105-2482  
Telephone: (415) 268-6237  
Facsimile: (415) 268-7522

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Paragraph beginning at line 31, page 2 has been amended as follows:

In particular, the present invention relates to the following modified kringle 5 peptides: NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub> (SEQ ID NO: 17); NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO: 18); Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO: 19); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO: 20); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH<sub>2</sub> (SEQ ID: NO 21); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 22); (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 23); (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 24); NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 25); (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 26); (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 27); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 28); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 29); (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 30); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 31); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub> (SEQ ID NO: 32); (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub> (SEQ ID NO: 33); NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 34); (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 35); (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 36); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 37);

(MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub> (SEQ ID NO: 38);  
(MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub> (SEQ ID NO: 39);  
NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -AEEA-MPA)-NH<sub>2</sub> (SEQ ID NO: 40);  
NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -AEEA<sub>n</sub>-MPA)-NH<sub>2</sub> (SEQ ID NO: 41); and  
other modified kringle 5 peptides.

Paragraph beginning at line 1, page 40 has been amended as follows:

**-- Example 1**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub>.3TFA (SEQ ID NO: 42) --**

Paragraph beginning at line 15, page 40 has been amended as follows:

**-- Example 2**

**Preparation of NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.3TFA (SEQ ID NO: 43) --**

Paragraph beginning at line 29, page 40 has been amended as follows:

**-- Example 3**

**Preparation of Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.3TFA  
(SEQ ID NO: 44) --**

Paragraph beginning at line 14, page 41 has been amended as follows:

**-- Example 4**

**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-  
Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.4TFA (SEQ ID NO: 45) --**

Paragraph beginning at line 2, page 42 has been amended as follows:

**-- Example 5**

**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH<sub>2</sub>.2TFA  
(SEQ ID NO: 46) --**

Paragraph beginning at line 18, page 42 has been amended as follows:

**-- Example 6**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH<sub>2</sub>.2TFA (SEQ ID  
NO: 47) --**

Paragraph beginning at line 16, page 43 has been amended as follows:

**-- Example 7**

**Preparation of (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 48)  
--**

Paragraph beginning at line 13, page 44 has been amended as follows:

**-- Example 8**

**Preparation of (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 49) --**

Paragraph beginning at line 7, page 45 has been amended as follows:

**-- Example 9**

**Preparation of NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-  
NH<sub>2</sub>.2TFA (SEQ ID NO: 50) --**

Paragraph beginning at line 4, page 46 has been amended as follows:

**-- Example 10**

**Preparation of (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 51) --**

Paragraph beginning at line 3, page 47 has been amended as follows:

**-- Example 11**

**Preparation of (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 52) --**

Paragraph beginning at line 1, page 48 has been amended as follows:

**-- Example 12**

**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( Nε-MPA)-NH<sub>2</sub>.3TFA (SEQ ID NO: 53)--**

Paragraph beginning at line 4, page 49 has been amended as follows:

**-- Example 13**

**Preparation of (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.3TFA (SEQ ID NO: 54) --**

Paragraph beginning at line 7, page 50 has been amended as follows:

**-- Example 14**

**Preparation of (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.3TFA (SEQ ID NO: 55) --**

Paragraph beginning at line 6, page 51 has been amended as follows:

**-- Example 15**

**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-( Nε-MPA)-NH<sub>2</sub>.TFA (SEQ ID NO: 56) --**

Paragraph beginning at line 4, page 52 has been amended as follows:

**-- Example 16**

**Preparation of (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub>.TFA (SEQ ID NO: 57) --**

Paragraph beginning at line 2, page 53 has been amended as follows:

**-- Example 17**

**Preparation of (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub>.TFA (SEQ ID NO: 58) --**

Paragraph beginning at line 1, page 54 has been amended as follows:

**-- Example 18**

**Preparation of NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( Nε-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 59) --**

Paragraph beginning at line 30, page 54 has been amended as follows:

**-- Example 19**

**Preparation of (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 60)--**

Paragraph beginning at line 26, page 55 has been amended as follows:

**-- Example 20**

**Preparation of (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 61) --**

Paragraph beginning at line 20, page 56 has been amended as follows:

**-- Example 21**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(Nε-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 62) --**

Paragraph beginning at line 17, page 57 has been amended as follows:

**-- Example 22**

**Preparation of (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub>.2TFA (SEQ ID NO: 63)--**

Paragraph beginning at line 13, page 58 has been amended as follows:

**-- Example 23**

**Preparation of (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub>.2TFA (SEQ ID NO: 64) --**

Paragraph beginning at line 7, page 59 has been amended as follows:

**-- Example 24**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 65) --**



Paragraph beginning at line 2, page 60 has been amended as follows:

**-- Example 25**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( Nε-AEEA<sub>n</sub>-MPA)-NH<sub>2</sub>.2TFA  
(SEQ ID NO: 66) --**

Paragraph beginning at line 3, page 61 has been amended as follows:

A peptide stability assay was performed. (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub>. 2TFA (SEQ ID NO: 67) was synthesized as described above and was identified MPA-K5. The non-modified counterpart peptide Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub> (SEQ ID NO: 12) was also synthesized as described above without the addition of 3-MPA and identified as K5.